HomeCompareCIFU vs JNJ

CIFU vs JNJ: Dividend Comparison 2026

CIFU yields 16.86% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CIFU wins by $29.9K in total portfolio value
10 years
CIFU
CIFU
● Live price
16.86%
Share price
$11.86
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$60.1K
Annual income
$4,747.32
Full CIFU calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CIFU vs JNJ

📍 CIFU pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCIFUJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CIFU + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CIFU pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CIFU
Annual income on $10K today (after 15% tax)
$1,433.39/yr
After 10yr DRIP, annual income (after tax)
$4,035.22/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CIFU beats the other by $49.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CIFU + JNJ for your $10,000?

CIFU: 50%JNJ: 50%
100% JNJ50/50100% CIFU
Portfolio after 10yr
$45.2K
Annual income
$4,718.36/yr
Blended yield
10.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CIFU
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CIFU buys
0
JNJ buys
0
No recent congressional trades found for CIFU or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCIFUJNJ
Forward yield16.86%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$60.1K$30.3K
Annual income after 10y$4,747.32$4,689.40
Total dividends collected$31.2K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CIFU vs JNJ ($10,000, DRIP)

YearCIFU PortfolioCIFU Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,386$1,686.34$10,592$272.30+$1.8KCIFU
2$15,205$1,952.11$11,289$357.73+$3.9KCIFU
3$18,510$2,239.64$12,123$472.89+$6.4KCIFU
4$22,353$2,547.94$13,141$629.86+$9.2KCIFU
5$26,794$2,875.73$14,408$846.81+$12.4KCIFU
6$31,891$3,221.49$16,021$1,151.60+$15.9KCIFU
7$37,706$3,583.49$18,122$1,588.22+$19.6KCIFU
8$44,306$3,959.81$20,930$2,228.20+$23.4KCIFU
9$51,756$4,348.45$24,792$3,191.91+$27.0KCIFU
10$60,126$4,747.32$30,274$4,689.40+$29.9KCIFU

CIFU vs JNJ: Complete Analysis 2026

CIFUStock

ETF Opportunities Trust - T-REX 2X Long CIFR Daily Target ETF is an exchange traded fund launched by ETF Opportunities Trust. The fund is managed by Tuttle Capital Management, LLC. It invests in public equity markets. The fund invests directly and through derivatives in stocks of companies operating across financials, financial services and capital markets sectors. It uses derivatives such as swaps and options to create its portfolio. It invests in growth and value stocks of companies across diversified market capitalization. ETF Opportunities Trust - T-REX 2X Long CIFR Daily Target ETF was formed on November 21, 2025 and is domiciled in the United States.

Full CIFU Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CIFU vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CIFU vs SCHDCIFU vs JEPICIFU vs OCIFU vs KOCIFU vs MAINCIFU vs ABBVCIFU vs MRKCIFU vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.